Publication Category: Hypofractionation

  • Ablative Radiotherapy for Unfavorable Prostate Tumors (ABRUPT): Analysis of Toxicity and Quality of Life from a Prospective Study

    ·

    ,

    Stefano Arcangeli, Chiara Chissotti, Federica Ferrario, Raffaella Lucchini, Maria Belmonte, Giorgio Purrello, Riccardo Ray Colciago, Elena De Ponti, Valeria Faccenda, Denis Panizza

    Published in International Journal of Radiation Oncology, Biology, Physics, 2024, July 04.

    Read article

  • Electromagnetic Transmitter-Based Prostate Gating for Dose-Escalated Linac-Based Stereotactic Body Radiation Therapy: An Evaluation of Intrafraction Motion

    ·

    ,

    De Bari, B.; Guibert, G.; Slimani, S.; Bashar, Y.; Risse, T.; Guisolan, N.; Trouillot, J.; Abel, J.; Weber, P.

    Published in  Curr. Oncol. 2024, 31, 962-974.

    Download

    Read article

  • State of the art and future challenges of urethra‑sparing stereotactic body radiotherapy for prostate cancer: a systematic review of literature

    ·

    ,

    Jennifer Le Guevelou, Davide Giovanni Bosetti, Francesco Castronovo, Antonio Angrisani, Renaud de Crevoisier & Thomas Zilli

    Published in World Journal of Urology, 2023, Sept 5th

    Download article

    Read article

  • Noninvasive inter- and intrafractional motion control in ultrahypofractionated radiation therapy of prostate cancer using RayPilot HypoCath™-a substitute for gold fiducial-based IGRT?

    ·

    , ,

    Johannes Berchtold , Carmen Winkler , Josef Karner , Michael Groher , Christoph Gaisberger, Felix Sedlmayer and Frank Wolf 

    Published in Strahlenther Onkol,  2023 Aug 25.  (Online ahead of print)

    Download article

    Read article

  • Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer (HYPO-RT-PC): patient-reported quality-of-life outcomes of a randomised, controlled, non-inferiority, phase 3 trial

    ·

    ,

    Per Fransson, PhD, Per Nilsson, PhD, Adalsteinn Gunnlaugsson, MD, Lars Beckman, MD, Björn Tavelin, BSc, David Norman, BSc, Camilla Thellenberg-Karlsson, MD, Prof Morten Hoyer, MD, Magnus Lagerlund, MD, Jon Kindblom, MD, Claes Ginman, MD, Bengt Johansson, MD, Kirsten Björnlinger, MD, Mihajl Seke, MD, Måns Agrup, MD, Prof Björn Zackrisson, MD, Elisabeth Kjellén, MD, Prof Lars Franzén, MD, Prof Anders Widmark, MD

    Read article

  • Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial

    ·

    David Dearnaley et al.

    Download Publication

    Read article